Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 02

127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study

Date

03 Dec 2022

Session

Poster viewing 02

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Jirapat Wonglhow

Citation

Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1016/annonc/annonc1123

Authors

J. Wonglhow1, P. Sunpaweravong1, C. Sathitruangsak1, S. Lucien Geater2, A. Dechaphunkul1

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, Faculty Of Medicine, Prince of Songkla University, 90110 - Songkhla/TH
  • 2 Division Of Respiratory And Respiratory Critical Care, Department Of Internal Medicine, Faculty Of Medicine, Prince of Songkla University, 90110 - Songkhla/TH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 127P

Background

There is no widely used prognostic tool to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC). We aimed to establish the prognostic score and demonstrate the real-world efficacy of FOLFOX4 in Thai patients.

Methods

Between August 2017 and December 2021, 58 patients with HCC treated with FOLFOX4 were identified. Efficacies of FOLFOX4, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were assessed. The prognostic score was constructed by stepwise cox proportional hazards regression combined with clinical experience to select variables for the best model.

Results

44 patients (76%) received FOLFOX4 as first-line systemic therapy. The efficacies of FOLFOX4 in the entire cohort were ORR of 8.6% and clinical benefit rate (CBR) of 29.3%. The median OS and PFS were 4.8 and 3.7 months, respectively. Four variables were included in the new prognostic score to predict 6-month overall survival based on their clinical relevance: L, the presence of lung metastasis; A, alcoholic cirrhosis; B, elevated total bilirubin; and S, sorafenib naive. The new prognostic "LABS" score classified all patients into low-, intermediate-, and high-risk groups, demonstrating the median OS of 9.3, 4.2, and 2.1 months, respectively (P<0.0001). The C-index and area under receiver operating characteristic curve of this score were 0.71 and 0.73, respectively.

Conclusions

The FOLFOX4 regimen showed comparable ORR, PFS, and OS efficacy to previous reports. The proposed prognostic “LABS” score clearly discriminated patients who would have the benefit from FOLFOX4. Therefore, we suggest that FOLFOX4 should be considered as one of the options for those who cannot approach immunotherapy and targeted therapy, particularly with a low-risk score. However, this model should be further evaluated in the larger cohorts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.